Beigene Says Updated Analysis From Phase 2 Rosewood Trial Of Brukinsa Plus Obinutuzumab Showed Clinically Meaningful Activity And Was Generally Well-tolerated In Pretreated Relapsed Or Refractory Follicular Lymphoma Patients
Portfolio Pulse from Benzinga Newsdesk
Beigene announced updated analysis from Phase 2 Rosewood trial of Brukinsa plus Obinutuzumab, showing clinically meaningful activity and good tolerance in pretreated relapsed or refractory follicular lymphoma patients. The data was highlighted at the International Conference on Malignant Lymphoma.
June 15, 2023 | 7:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beigene's Phase 2 Rosewood trial of Brukinsa plus Obinutuzumab showed positive results, potentially benefiting the company's stock.
The positive results from the Phase 2 Rosewood trial indicate that Brukinsa plus Obinutuzumab has potential in treating follicular lymphoma patients. This could lead to increased demand for the drug and higher revenues for Beigene, positively impacting BGNE stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100